Trials / Withdrawn
WithdrawnNCT00478270
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
An Open Label Study to Assess the Effect of Intravenous Loading Doses of Bondronat on Metastatic Bone Pain in Patients With Breast Cancer and Skeletal Metastases.
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This single arm study will assess the efficacy of loading doses of intravenous Bondronat in reducing pain in patients with breast cancer and metastatic bone disease experiencing moderate to severe bone pain. Patients will receive an intravenous infusion of 6mg Bondronat on days 1, 2 and 3. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ibandronate [Bondronat] | 6mg iv on days 1-3 |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2007-05-24
- Last updated
- 2017-08-16
Locations
6 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT00478270. Inclusion in this directory is not an endorsement.